医疗器械公司AngioDynamics(ANGO)近日重申,在截至2026财年的全年业绩展望中,公司持续预计关税政策将对其财务表现产生400万至600万美元的影响。这一预估范围与先前披露的预期保持一致,反映出公司在全球供应链成本管理方面所面临的持续挑战。
医疗器械公司AngioDynamics(ANGO)近日重申,在截至2026财年的全年业绩展望中,公司持续预计关税政策将对其财务表现产生400万至600万美元的影响。这一预估范围与先前披露的预期保持一致,反映出公司在全球供应链成本管理方面所面临的持续挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.